Novo Nordisk A's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the fourth quarter 2025 to a ratio of 4.21, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the fourth quarter 2025. Average receivable collection period, for the Novo Nordisk A in Dec 31 2025 quarter, has decreased to 87 days, compared to 94 days, in the 0 quarter.

If we take a look into Healthcare sector 278 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Dec 31 2025 from to 1994.

What is Receivable Turnover Ratio?
What is Novo Nordisk A Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NVO Receivables Turnover Ratio	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	11.49 %	11.49 %	11.49 %	11.49 %	3.9 %
Y / Y Revenue Change	11.14 %	-	-	-	-
Receivable Turnover Ratio (TTM)	4.21	3.88	3.99	4.1	4.22
NVO's Total Ranking	# 1994	#	#	#	#
Accounts Receivable average collection period days	87	94	91	89	87
Seq. Receivable Change	-0 %	0 %	0 %	11.49 %	-0 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 72
Healthcare Sector	# 279
Overall Market	# 1994

Receivable Turnover Ratio Statistics
High	Average	Low
1.04	0.78	0.57
(Dec 31 2018)		(Dec 31 2025)

NVO Company Profile • Back to NVO Efficiency Comparisons • Compare NVO Receivables Turnover Ratio to its Competitors

Financial Statements
Novo Nordisk A's Accounts Receivable	$ 11,134 Millions	Visit NVO's Balance sheet
Novo Nordisk A's Sales TTM	$ 46,820 Millions	Visit NVO's Income Statement
Sources of NVO's Revenues		Visit NVO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NVO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NVO's Growth Rates	NVO's Roa	NVO's Inventory Turnover Ratio	NVO's Dividend Comparisons
NVO's Profitability Ratios	NVO's Roi	NVO's Asset Turnover Ratio	NVO's Dividend Growth
NVO's Valuation Ratios	NVO's Roe	NVO's Financial Strength Ratios	NVO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Dec 31 2025	Receivable at quarter ending Dec 31 2025
Integrated Biopharma Inc	11.30	$ 51.068 Millions	$ 4.521 Millions
Nrc Health	11.28	$ 137.390 Millions	$ 12.176 Millions
Lftd Partners Inc	11.18	$ 36.921 Millions	$ 3.303 Millions
Petvivo Holdings Inc	11.10	$ 0.791 Millions	$ 0.071 Millions
Uniqure N v	10.98	$ 16.098 Millions	$ 1.466 Millions
Inmed Pharmaceuticals Inc	10.98	$ 4.507 Millions	$ 0.410 Millions
National Healthcare Corp	10.92	$ 1,517.781 Millions	$ 138.939 Millions
Novavax inc	10.92	$ 1,123.479 Millions	$ 102.881 Millions
Vivos Therapeutics Inc	10.91	$ 16.542 Millions	$ 1.517 Millions
Cue Biopharma Inc	10.70	$ 27.466 Millions	$ 2.566 Millions
Inventiva S a	10.68	$ 13.898 Millions	$ 1.301 Millions
Lifeloc Technologies Inc	10.58	$ 9.027 Millions	$ 0.853 Millions
Exact Sciences Corporation	10.49	$ 3,245.310 Millions	$ 309.460 Millions
Bioaffinity Technologies Inc	10.37	$ 6.162 Millions	$ 0.594 Millions
Bioxcel Therapeutics Inc	10.27	$ 0.642 Millions	$ 0.063 Millions
Utah Medical Products Inc	10.25	$ 38.001 Millions	$ 3.706 Millions
Addus Homecare Corp	10.15	$ 1,421.874 Millions	$ 140.113 Millions
Biolife Solutions Inc	10.11	$ 96.118 Millions	$ 9.506 Millions
Scisparc Ltd	10.07	$ 0.856 Millions	$ 0.085 Millions
Aquestive Therapeutics Inc	10.03	$ 44.545 Millions	$ 4.441 Millions
Viemed Healthcare Inc	9.97	$ 270.280 Millions	$ 27.120 Millions
Veracyte Inc	9.94	$ 489.532 Millions	$ 49.270 Millions
Zomedica Corp	9.93	$ 31.278 Millions	$ 3.150 Millions
Sanuwave Health Inc	9.92	$ 44.051 Millions	$ 4.439 Millions
Sunshine Biopharma Inc	9.91	$ 36.306 Millions	$ 3.662 Millions
Vireo Growth Inc.	9.89	$ 268.769 Millions	$ 27.182 Millions
Madrigal Pharmaceuticals Inc	9.87	$ 958.403 Millions	$ 97.105 Millions
International Stem Cell Corporation	9.86	$ 9.100 Millions	$ 0.923 Millions
Kestra Medical Technologies Ltd	9.85	$ 79.728 Millions	$ 8.092 Millions
Sol gel Technologies Ltd	9.85	$ 19.388 Millions	$ 1.968 Millions

Date modified: 2026-09-10T03:11:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.